PanGenex finalizes partnership with BulovaTech Labs

PanGenex Corporation (Pink Sheets: PGCX), a global nutraceutical and dietary supplement manufacturer and marketer, announced today that it has finalized a strategic partnership with BulovaTech Labs, Inc., (“LABS”), a wholly-owned subsidiary of Bulova Technologies Group Inc., (Pink Sheets: BLVT). The new partnership supports the joint development and commercialization of PanGenex’s nutraceutical and healthcare products. The partnership includes an exclusive collaboration agreement that will accelerate the development of proprietary technologies and products, which will be marketed by PanGenex under the PanGenex trademark.

“BulovaTech Labs is an ideal partner for PanGenex,” said Jim Mosbaugh, COO of PanGenex. “Through LABS' parent company, Bulova Technologies Group, LABS has access to substantial technical and financial resources. Together, we can continue to drive momentum for sales of unique, condition-specific, and proven effective nutraceutical and healthcare products worldwide.”

PanGenex has developed unique patent-protected products, which effectively address cardiac health, soft tissue calcification, and blood lipids. PanGenex's trademarked and patented products include: Calci-Clear ™, LIPIDEME ™ and Omeganol ™, all of which are showing strong physician and end user acceptance in the $538 Billion soft tissue calcification treatment market. “LABS is an exciting venture that seeks to invest in high-growth ground floor opportunities, including the rapidly growing market for nutraceuticals. We are confident that by collaborating with PanGenex we can rapidly bring successful commercial products to markets worldwide,” stated BulovaTech Chairman John Stanton.